Detection and molecular characterization of vancomycin resistant Staphylococcus aureus from clinical isolates by Shady, Abu HM et al.
African Journal of Biotechnology Vol. 11(99), pp. 16494-16503, 11 December, 2012  
Available online at http://www.academicjournals.org/AJB 
DOI: 10.5897/AJB12.1937 






Full Length Research Paper 
 
Detection and molecular characterization of 
vancomycin resistant Staphylococcus aureus from 
clinical isolates 
 
Abu Shady, H. M.1*, El-Essawy, A. K.2, Salama, M. S.3 and El-Ayesh, A. M.4 
 
1
Microbiology Department, Faculty of Science, Ain Shams University, Cairo, Egypt. 
2
Microbiology Department, Ain Shams University Specialized Hospital, Cairo, Egypt. 
3
Entomology Department (Molecular Biology Unit), Faculty of Science, Ain Shams University, Cairo, Egypt. 
4
Zagazig University Hospitals, Zagazig, Egypt. 
 
Accepted 9 November, 2012 
 
Until now, few strains of vancomycin resistant Staphylococcus aureus (VRSA) have been reported 
worldwide. The disk diffusion method for determination of vancomycin sensitivity frequently 
misclassifies intermediately susceptible isolates to fully susceptible. However, non-automated 
minimum inhibitory concentration (MIC) detection methods are the gold standards. In the present study, 
439 Gram positive clinical isolates were collected. Among them, 220 Staphylococcus aureus were 
identified. Multiplex polymerase chain reaction (PCR) detection method for vancomycin resistant S. 
aureus (VRSA) was developed for detection of both vanA gene (for vancomycin resistance) and nuc 
gene (specific for S. aureus) in a single step PCR compared to conventional non-automated disc 
diffusion and MIC detection methods. Molecular typing of VRSA isolates was performed using randomly 
amplified polymorphic (RAPD) DNA assay technique. The results show 10 VRSA isolates detected by 
disc diffusion method and MIC determination. Five out of them harbored vanA gene that were detected 
by multiplex PCR and most of them showed low clonal diversity.  
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It was initially feared that Staphylococcus aureus would 
acquire the van genes that code for vancomycin 
resistance in Enterococcus species (Cercenado et al., 
1998). Several years prior to the report of the first clinical 
vancomycin intermediate sensitive S. aureus (VISA) 
isolate, laboratory strains of VISA and vancomycin 
resistant S. aureus (VRSA) that had much thicker cell 
walls than the sensitive parent strains were produced 
(May et al., 1998). Subsequent investigators 
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upregulated in VRSA isolates, leading to thicker and 
more-disorganized cell walls (Rybak and Akins, 2001). 
Furthermore, the altered cell walls that appear to have a 
reduced affinity for vancomycin as soluble targets are 
able to bind more antibiotics in the presence of 
vancomycin-resistant isolates (Fahmy and El-Hendy, 
2002). Hence, the role of penicillin-binding proteins 
(PBPs) in vancomycin resistance was unclear (Sieradzki 
and Tomasz, 1997).  
The most common way VRSA are transmitted in the 
health care setting is from patient to patient via the hands 
of health care workers (Murray, 2000). The risk of such 
transmission may increase in colonized health care 
workers with sinus or upper respiratory infections and in 





administration of more than three antibiotics is associated 
with the development of VRSA infection amongst patients 
already colonized with VRSA (Harbarth et al., 2002). 
Infection rates increased with the prolonged duration of 
preoperative hospital stay (Livermore, 2000).  
Six types of vancomycin resistance have been 
characterized on both a phenotypic and a genotypic basis 
in enterococci. Five of these types (VanA, B, D, E, and G) 
correspond to acquired resistance; one type (VanC) is an 
intrinsic property of Enterococcus gallinarum and 
Enterococcus casseliflavus–Enterococcus flavescens. 
Classification of glycopeptide resistance is currently 
based on the primary sequence of the structural genes 
for the resistance ligases rather than on the levels of 
resistance to glycopeptides because the minimum 
inhibitory concentration (MIC) ranges of vancomycin and 
teicoplanin against the various types overlap. VanA-type 
strains display high levels of inducible resistance to both 
vancomycin and teicoplanin, whereas VanB-type strains 
have variable levels of inducible resistance to 
vancomycin only (Arthur et al., 1996a; b). VanD-type 
strains are characterized by constitutive resistance to 
moderate levels of the 2 glycopeptides (Depardieu et al., 
2003b) while VanC-, VanE-, and VanG-type strains are 
resistant to low levels of vancomycin but remain 
susceptible to teicoplanin (Reynolds and Courvalin, 
2005). 
Although the six types of resistance involve related 
enzymatic functions, they can be distinguished by the 
location of the corresponding genes and by the mode of 
regulation of gene expression. The vanA and vanB 
operons are located on plasmids or in the chromosome 
(Arthur et al., 1996a; b), whereas the vanD (Depardieu et 
al., 2003b), vanC (Arias et al., 2000), vanE (Abadia et al., 
2002), and vanG (Depardieu et al., 2003a) operons have, 
thus far, been found only in the chromosome. 
 
 
MATERIALS AND METHODS 
 
Patient and sampling 
 
The samples were collected from outpatient clinics as well as 
inpatient departments mainly from intensive care unit and 
orthopedic department at Zagazig University hospitals, Egypt. 
These samples harbored mainly from surgical sites by swabbing or 
from urine, blood and sputum samples. 
 
 
Bacterial cultivation and isolation 
 
The collected samples were cultivated on nutrient agar, blood agar, 




Bacterial identification  
 
Morphology and microscopy  
 
Colonies were examined for morphology and  Gram  positive  grape  




like clusters of Staphylococci (Kloos and Bannerman, 1995).  
 
 
Biochemical reactions  
 
Catalase test, tube and slide coagulase test, mannitol salt agar and 
deoxyribonuclease (Oxoid) test were performed. 
 
 
Antibiotic susceptibility test 
 
Disc diffusion method  
 
Sensitivity of the isolated strains to methicillin (5 µg), vancomycin 
(30 µg), penicillin G (10 µg), and oxacillin (30 µg) (antibiotics from 
Oxoid) was performed on Mueller-Hinton agar plates (Oxoid). VRSA 
isolates were subjected to further antibiotic sensitivity tests. 
 
 
Determination of minimum inhibitory concentration (MIC)  
 
Broth dilution method was done in tubes for different concentration 
of vancomycin (4, 8, 16, 32, 64 mg/L). Broth dilution was performed 
in Muller-Hinton broth and read after 24 h, as recommended by the 
National Committee for Clinical Laboratory Standards (NCCLS). 
MIC for different isolates to vancomycin differentiates the resistant 
from the sensitive strains. By definition, VRSA shows in-vitro MICs 
of > 4 mg/L (Rybak et al., 2001). However, other workers reported 
that the most resistant strains bear the vanA gene cluster and these 
are generally recognizable as MICs of vancomycin are usually 
found to be in the range 32 to 64 mg/L (Hawkey, 2009). VanA-type 
strains display high levels of inducible resistance to both 
vancomycin and teicoplanin, whereas VanB-type strains have 
variable levels of inducible resistance to vancomycin only (Arthur et 
al., 1996). VanD-type strains are characterized by constitutive 
resistance to moderate levels of the 2 glycopeptides (Depardieu et 
al., 2003). VanC-, VanE-, and VanG-type strains are resistant to low 
levels of vancomycin but remain susceptible to teicoplanin 
(Reynolds and Courvalin, 2005). 
 
 
Multiplex polymerase chain reaction (PCR)  
 
The primers were one pair for (vanA) gene detection “vancomycin 
resistance gene” (forward primer EA1, 5΄-
GGGAAAACGACGACAATTGC-3΄ and reverse primer EA2, 5΄-
GTACAATGCGGCCGTTA-3΄), and the other pair of primer for (nuc) 
gene detection “confirmatory gene for S. aureus” (forward primer 
TN1, 5΄-GACTATTATTGGTTGATCCACCTG-3΄ and reverse primer 




Bacterial isolates  
 
From an overnight shaken culture, 1.5 ml of staphylococci in brain 




DNA extraction  
 
The bacterial cells were suspended in 150 µl of a solution 
containing 50 mM Tris hydrochloride (pH 8.0), 10 mM EDTA, and 
7% sucrose with lysozyme lysostaphin (5 mg/ml; AMBI, Trowbridge, 
UK) and incubated at 37°C for 10 min. The resulting protoplasts 
were lysed with sodium dodecyl sulfate (1.25%) for 10 min on ice, 
and   after   two   phenol-chloroform   extractions,   total   DNA   was  




Table 1. Distribution of MRSA and VRSA isolated from different 
specimens.  
 
Types of specimen 
MRSA isolates VRSA isolates 
Number/Total Number/Total 
Pus 38/94* 6/94** 
Abscess 15/35 1/35 
Blood 16/71 1/71 
Urine 3/9 1/9 
Sinusitis 1/1 0/1 
Catheters 1/ 2 1/2 
Sputum 1/7 0/7 
Peritoneal  1/1 0/1 
 
*P < 0.05 compared to blood, P > 0.05 compared to abscess, sputum, 
urine, sinusitis, v. catheter and peritoneal fluid and **P > 0.05 compared 




recovered in the supernatant after centrifugation (15,000 g, 5 min). 
 
 
PCR amplification  
 
In brief, 1 to 3 µL of total DNA was subjected to multiplex PCR 
amplification in a 100 µL reaction mixture containing PCR buffer [10 
mM Tris-HCl (pH 9.0), 50 mM KCl, 1.5 Mm MgCl2, 0.1% Triton X-
100, 0.2 mg/ml of bovine serum albumin, 50 µM each 
deoxynucleoside triphosphate, of each of the 2 primer pairs, and 2 
U of Taq polymerase (QBIOgene, Montreal, Quebec, Canada)]. 
Amplification was carried out with the following thermal cycling 
profile: 3 min at 94°C and 30 cycles of amplification consisting of 1 
min at 94°C, 1 min at 54°C, and 1 min at 72°C, and 7 min at 72°C 
for the final extension. 
 
 
Detection of PCR product  
 
DNA fragments were analyzed by electrophoresis in 0.5X TBE 
(Tris-borate-EDTA) on a 1% agarose (Sigma-Aldrich) gel stained 
with ethidium bromide (Sigma-Aldrich).  
 
  
Molecular typing  
 
Molecular typing was performed using randomly amplified 
polymorphic (RAPD) DNA assay (Tambic et al., 1997). The arbitrary 
primers (From Neest) that were used for RAPD typing are: OPA-05 
5΄- AGGGGTCTTG -3΄; OPB-12 5΄ - CCTTGACGCA -3΄; OPC-09 
5΄ -CTCACCGTCC - 3΄; OPD-05 5΄ - TGAGCGGACA - 3΄. The four 
primers that were used after a good ability to discriminate S. aureus 
strains for typing purposes are shown in the pilot experiments. Each 
reaction mixture included 200 µM nucleotide (each) (Sigma), 5 µL 
of 10× reaction buffer, 500 nM primer, 50 ng template DNA, and 2U 
of Taq XL DNA polymerase (Northum-bria Biochemicals Ltd., 
Cramlington, United Kingdom), and the mixture was made up to 50 
µL with molecular biology-grade water. This mixture was overlaid 
with 50 µL of mineral oil (Sigma). RAPD cycling parameters were 
94°C for 5 s, 34°C for 30 s, and 72°C for 1 min for 35 cycles, with a 
final extension of 72°C for 5 min. Reactions were carried out in a 
Hybaid Thermal Reactor (Perkin Elmer). The products were 
electrophoresed on 2% agarose gels in 0.5X TBE (Tris, borate, 
EDTA) buffer. Synthetic PCR molecular size markers were included 
in each gel. The gels were run for 5 to 6 h at 60 V to allow the 
complete separation of the bands. 
Statistical analysis 
 
Data analysis was performed using Chi-squared test, Fisher's exact 
test and T-test. Polymorphism analysis was performed and 





Two hundred and twenty (220) S. aureus strains were 
defined from 439 Gram positive specimens (50.1%). 
Methicillin resistant S. aureus were 76 isolates (34.5%), 
and vancomycin resistant was 10 isolates (4.5%). MRSA 
isolates among S. aureus from intensive care unit (ICU) 
were 29.0% (27/93), 22.2% (10/45) from orthopedic 
department and 47.6% (39/82) from outpatient clinics. 
Only statistically significant difference was observed 
regarding MRSA isolates between outpatient and each of 
ICU (P < 0.05) and orthopedic ward (P < 0.01), while no 
statistical difference between ICU and orthopedic ward 
were detected (P > 0.05). VRSA isolates from ICU, 
orthopedic unit and outpatient clinics were 6.5% (6/93), 
6.7% (3/45) and 1.2% (1/82), respectively. VRSA isolates 
distribution to different wards showed no statistical 
significance (P< 0.05). 
Table 1 shows that MRSA isolates from pus were 
40.4% (38/94) with statistical significant difference 
compared to blood (16/71, 22.5%), P < 0.05. However, 
there were no significant differences when compared with 
pus with other types of specimens (P > 0.05). On the 
other hand, for VRSA isolates, there were no statistically 
significant differences when pus was compared with 
other specimens (P > 0.05), and there was no statistical 
significance for patients’ age or gender on the distribution 
of VRSA and MRSA. Moreover, all VRSA isolates were 
sensitive to cefoperazone, trimethoprime, amikin and 
rifampin and resistant to clavulinic acid, cefoxtin, 
cefazolin, oxacillin, tetracyclin, vancomycin and cefexime. 
Table 2 shows that five isolates were identified as VRSA 
by  multiplex  PCR  out  of  10  isolates   by   conventional  




Table 2. Distribution of the conventional and molecular detected VRSA isolates.  
 
Specimen Ward Multiplex PCR Conventional method Isolate 
wound Orthopedic - + 1 
wound Orthopedic - + 2 
wound Orthopedic - + 3 
Ven. Catheter ICU - + 4 
Abscess ICU - + 5 
Blood ICU + + 6 
Pus ICU + + 7 
Urine ICU + + 8 
Pus ICU + + 9 
Pus outpatient + + 10 
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Figure 1. Multiplex PCR for detection of vanA and nuc genes. M, Molecular size marker; 
lanes 1 to 10 (isolates 1 to 10), the 10 tested VRSA strains (5 of them “isolates 1 to 5” are 
negative for vanA gene, while 5 strains “isolates 6 to 10” are positive for vanA gene at 
molecular size of 732 bp); lanes 11 to 15 (isolates 11 to 15), methicillin and vancomycin 
sensitive S. aureus strains “negative controls”. All the tested isolates “1 to 15” were 
confirmed as S. aureus as they are positive for nuc gene with PCR product molecular size 




methods (50%).  
Figure 1 shows the multiplex PCR for specific and rapid 
identification of VRSA in one step using a pair of primers. 
The first one is specific for detection of vancomycin 
resistant gene (vanA) with product molecular size of 732 
bp. The second for nuc gene for identification of S. 
aureus with product molecular size of 218 bp. PCR 
results show that strains of isolates 6, 7, 8, 9 and 10 were 
positive for both vanA gene and nuc gene. Figures 2 to 5 
show the random amplified polymorphism (RAPD) of 15 
isolates. Polymorphism analysis was performed using 
statistical analysis illustrated in dendrogram and similarity 
index (Figure 6; Table 3). It was observed that the 
dendrogram divided the isolates at the value of 15 on the 
scale into four groups; the first group included the 
isolates 5, 8, 7, 4, 2, 3, 9, 11, 10, 6 (which include all the 
vancomycin resistant strains except strain 1), the second 
group included isolates 13, 14, 15 (which includes all the 
vancomycin sensitive isolates except 11, 12), the third 
group included isolate  1  and  the  fourth  group  included  






Figure 2. Pattern of RAPD using operon D05 primer for the 15 isolates previously tested 
by PCR for vanA and nuc genes. M, Molecular size marker; lanes 1 to 10 (isolates 1 to 
10), the 10 tested VRSA strains (5 of them “isolates 1 to 5” are negative for vanA gene, 5 
strains “isolates 6 to 10” are positive for vanA gene); lanes 11 to 15 (isolates 11 to 15), 
methicillin and vancomycin sensitive S. aureus strains “negative controls”. All the tested 






Figure 3. Pattern of RAPD using operon A 05 primer for the 15 isolates previously tested by 
PCR for vanA and nuc genes. M: Molecular size marker, Lanes 1 to10 (isolates 1 to 10), the 10 
tested VRSA strains (5 of them “isolates 1 to 5” are negative for vanA gene, while 5 strains 
“isolates 6 to 10” are positive for vanA gene); lanes 11 to 15 (isolates 11 to 15), methicillin and 
vancomycin sensitive S. aureus strains “negative controls”. All the tested isolates “1 to 15” were 




isolate 12 (Figure 6). The 5 VRSA isolates “vanA gene 
positive” (6, 7, 8, 9, 10) showed level of similarity with 
range between 0.4 to 1.0. On the other hand, the 






Vancomycin resistance in  S. aureus  has  emerged  over  
the last ten years. The most resistant strains (fortunately 
rare) bear the vanA gene cluster (Hawkey, 2009). The 
molecular target of glycopeptide antibiotics is the D-
alanyl-D-alanine (D-Ala-D-Ala) terminus of growing 
peptidoglycan, the rigid polymer which protects bacterial 
cells from osmotic lysis. By binding to this terminal 
dipeptide, glycopeptides antibiotics interfere with proper 
cell wall formation, which results in an eventual cell death 
(Barna and Williams, 1984). Nevertheless, glycopeptide-
resistant organisms avoid such  a  fate  by  modifying  the  






Figure 4. Pattern of RAPD using operon B12 primer for the 15 isolates previously tested by PCR for 
vanA and nuc genes. M, Molecular size marker; lanes 1 to 10 (isolates 1 to 10), the 10 tested VRSA 
strains (5 of them “isolates 1 to 5” are negative for vanA gene, while 5 strains “isolates 6 to 10” are 
positive for vanA gene); lanes 11 to 15 (isolates 11 to 15), methicillin and vancomycin sensitive S. 
aureus strains “negative controls”. All the tested isolates “1 to 15” were confirmed as S. aureus as 






Figure 5. Pattern of RAPD using operon C 09 primer for the 15 isolates previously tested by PCR for 
vanA and nuc genes. M, Molecular size marker; lanes 1 to 10 (isolates 1 to 10), the 10 tested VRSA 
strains (5 of them “isolates 1 to 5” are negative for vanA gene, while 5 strains “isolates 6 to 10” are 
positive for vanA gene); lanes 11 to 15 (isolates 11 to 15), methicillin and vancomycin sensitive S. 
aureus strains “negative controls”. All the tested isolates “1 to 15” were confirmed as S. aureus as they 




drug’s peptide target, specifically by modifying it to the 
depsipeptide D-alanyl-D-lactate (D-Ala-D-Lac) (Walsh et 
al., 1996). The biosynthetic machinery required to effect 
this transformation in vancomycin-resistant Enterococcus 
faecium is found on a transposable element, Tn1546, 
which incorporates five genes necessary and sufficient to  






Figure 6. Similarity dendrogram for the 15 strains tested by RAPD. Isolates 1 to 10, The 10 tested VRSA 
strains (5 of them “isolates 1 to 5” are negative for vanA gene, while 5 strains “isolates 6 to 10” are positive for 
vanA gene); Isolates 11 to15, methicillin and vancomycin sensitive S. aureus strains “negative controls”. All the 




confer high-level inducible glycopeptide resistance 
(Arthur et al., 1993). Two of these gene products, VanR 
and VanS, are required for the vancomycin-induced 
resistance response and are members of a two 
component regulatory system directing the transcription 
of vanH, vanA, and vanX. These genes encode the three 
proteins that are necessary for D-Ala-D-Lac synthesis 
and are thus essential for glycopeptide resistance (Arthur 
et al., 1992).  
VanA is the pivotal enzyme, producing the ester D-Ala-
D-Lac instead of the usual D-Ala-D-Ala dipeptide for 
incorporation into peptidoglycan precursors (Bugg et al., 
1991). VanH is an aldo-keto acid reductase (D-lactate 
dehydrogenase [D-LDH]) that supplies VanA with 
substrate by converting pyruvate into D-lactate (Bugg et 
al., 1991). Courvalin (2006) reported that vanA is the 
most frequently encountered type of glycopeptides 
resistance in Enterococci and was reported as the only 
one detected in S. aureus. The prototype Tn1546 VanA-
type resistance element, which was originally detected on 
a plasmid in an E. faecium clinical isolate, is an 11-kb 
transposon. It encodes nine polypeptides that can be 
assigned to various functional groups: transposition 
(ORF1 and ORF2), regulation of resistance gene 
expression (VanR and VanS), synthesis of the d-Ala-d-
Lac depsipeptide (VanH and VanA), and hydrolysis of 
peptidoglycan precursors (VanX and VanY); the function 
of VanZ remains unknown.  
In this study carried on patients in Zagazig University 
Hospital, VRSA strains were isolated from 4.5% of 
patients infected with S. aureus according to conventional 
methods while only half of this percentage (2.3%) by 
multiplex PCR for vanA and nuc genes (vanA for 
vancomycin resistance and nuc for S. aureus). This 
relatively high percentage of VRSA in the present study 
may be explained by administration of multiple 
prophylactic and post-operative antibiotics with prolonged 
hospitalization. The hospital is  an  ideal  environment  for  




Table 3. Similarity index for the 15 tested isolates according to RAPD.  
 
Isolates 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
1               
2 0.5              
3 0.4 0.8             
4 0.4 0.8 0.6            
5 0.5 0.7 0.7 0.8           
6 0.0 0.4 0.4 0.5 0.6          
7 0.5 0.7 0.7 0.8 0.9 0.5         
8 0.5 0.6 0.6 0.7 1.0 0.6 0.8        
9 0.3 0.5 0.4 0.4 0.6 0.6 0.5 0.7       
10 0.2 0.4 0.2 0.4 0.4 0.4 0.4 0.4 0.6      
11 0.5 0.5 0.5 0.7 0.7 0.5 0.7 0.7 0.7 0.6     
12 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.3 0.1    
13 0.5 0.5 0.4 0.6 0.6 0.3 0.7 0.7 0.4 0.4 0.6 0.3   
14 0.4 0.3 0.2 0.5 0.5 0.3 0.5 0.5 0.4 0.3 0.5 0.2 0.8  
15 0.4 0.3 0.3 0.3 0.3 0.2 0.4 0.5 0.2 0.3 0.5 0.3 0.5 0.5 
 
Isolates 1 to 10: the 10 tested VRSA strains (5 of them “isolates 1 to 5” were negative for vanA gene, while 5 strains “isola tes 6-10” were 
positive for vanA gene. Isolates 11 to 15, Methicillin and vancomycin sensitive S. aureus strains “negative controls”. All the tested isolates 




the transmission of pathogens, because patients with 
similar disease and susceptibilities are housed in an 
enclosed community and also because of the duration of 
stay in hospital (Kariyama and Kumon, 2001). This 
emergence was significantly marked in hospitals that had 
been endemic with strains of methicillin-resistant 
staphylococci and followed the policy of empirical use of 
glycopeptides. Extensive use of glycopeptides 
(vancomycin or teicoplanin) allowed selection of resistant 
strains of S. aureus (Rybak and Akins, 2001). 
Glycopeptide-resistant mutants of S. aureus have been 
experimentally selected by gradually increasing the levels 
of vancomycin present during in-vitro growth (Shonekan 
et al., 1992). 
The presence of vancomycin hetero-resistance 
phenomenon in staphylococci may increase the need to 
modify the methods used for detection of vancomycin 
resistance in the clinical microbiology laboratory (Singh et 
al., 2003). There was no statistical significance for the 
distribution of VRSA or MRSA among different patient’s 
age or gender in the current study. It was reported that 
patients in the ICU and other critically ill patients are at 
high risk for co-colonization with MRSA and possibly, 
VRSA (Merrer et al., 2000). On the contrary, results in the 
present study show high level of MRSA in inpatient 
wards. However, the highest percentage of MRSA was 
observed in outpatient isolates (47.6%) compared to 
inpatients wards of ICU (29%) and orthopedic unit 
(22.2%) with statistically significant P values of < 0.05 
and < 0.01 respectively. On the other hand, no 
statistically significant difference was observed between 
different wards regarding VRSA distribution. MRSA and 
VRSA isolates from pus (or wound) compared to other 
types of specimens also had no significant difference 
except when compared with MRSA isolates from blood. 
MRSA isolates from pus (40.4%) was significantly higher 
than that from blood (22.5%), (P < 0.05).  
Furthermore, all VRSA isolates were sensitive to 
cefoperazone, trimethoprime, amikin and rifampin and 
resistant to clavulinic acid, cefoxtin, cefazolin, oxacillin, 
tetracyclin, vancomycin and Cefexime. This result agrees 
with Phillips et al. (2003), who reported that all isolates 
resistant to glycopeptides are resistant to methicillin and 
susceptible to rifampin, trimethoprime, piperacillin and 
cefoperazone. Ten vancomycin-resistant S. aureus 
isolates were reported in the present study by 
conventional methods (disc diffusion method and MIC 
determination). Only five of them were positive for vanA 
gene by multiplex PCR, although all were confirmed as S. 
aureus by multiplex PCR (nuc gene positive).  
VanA-type strains display high levels of inducible 
resistance to both vancomycin and teicoplanin, whereas 
VanB-type strains have variable levels of inducible 
resistance to vancomycin only (Arthur et al., 1996). 
VanD-type strains are characterized by constitutive 
resistance to moderate levels of the two glycopeptides 
(Depardieu et al., 2003b). VanC-, VanE-, and VanG-type 
strains are resistant to low levels of vancomycin but 
remain susceptible to teicoplanin (Reynolds and 
Courvalin, 2005). Some studies have reported the 
emergence of VRSA in clinical isolates that, by definition, 
show in-vitro MICs of > 4 mg/L (Rybak et al., 2001). The 
present study depended on the same criteria for 
detection of the ten vancomycin resistant isolates. 
However, other workers reported that the most resistant 
strains  bear  the   vanA   gene   cluster   and   these   are  




generally recognizable as MICs of vancomycin are 
usually found to be in the range 32-64 mg/L (Hawkey, 
2009). This may explain why not all vancomycin resistant 
strains by conventional methods were PCR positive for 
vanA gene in the present study. All our VRSA isolates 
showed MIC for vancomycin of 32 mg/L, which means 
that at this level of MIC, the VRSA isolate may have vanA 
gene or not (Hawkey, 2009). So, this PCR method is 
confirmatory for the VRSA isolate if it gave positive result 
(confirm nuc gene for S. aureus and vanA gene for 
vancomycin resistance), but if positive for nuc gene and 
negative for vanA gene, it cannot exclude the possibility 
to be VRSA. It should be regarded that there are van 
resistance genes other than vanA (which was concerned 
in the current study); these genes include vanB, vanC, 
vanD and vanE and vanG (Depardieu et al., 2004).  
The transfer of the vanA gene cluster from Enterococci 
to S. aureus has been demonstrated in laboratory by in 
vitro experiment and also on the skin of mice. This finding 
has raised concern about the possibility of occurrence of 
such mechanism of genetic transfer in clinical isolates of 
Staphylococci, which often co-colonize wound infection 
sites with Enterococci. Until now, few studies have shown 
the presence of any of van genes clusters in clinical 
isolates of staphylococci and so such mechanism could 
not be proved (Fridkin, 2001). Our current study, in 
addition to other reports (Depardieu et al., 2004) support 
this mechanism, as the vanA gene was detected in 
clinical isolates of VRSA. The resistance of Staphylococci 
to vancomycin has been found to be reversible under 
laboratory conditions (Rybak and Akins, 2001). One 
study indicated that vancomycin resistance in S. aureus 
may occur under the selective pressure of prolonged 
vancomycin use and that the resistance to vancomycin in 
S. aureus is reversible on removal of the drug. Moreover, 
thickening of the bacterial cell wall may be the underlying 
mechanism for vancomycin resistance in these bacteria 
(Cui et al., 2003). Actually, thickening of the cell wall of 
vancomycin-resistant staphylococci has been found to be 
associated with complex re-organization of cell wall 
metabolism with extra cell wall material showing reduced 
peptidoglycan cross-linking of D-Ala-D-Ala termini of side 
chains (Walsh and Howe, 2002). Cui et al. (2003) 
reported that in view of low level vancomycin resistance 
and the absence of van genes or any alteration in the 
terminal D-alanyl-D-alanine residues of peptidoglycan, it 
would be reasonable to consider the cell wall thickening 
as the major contributor to vancomycin resistance of S. 
aureus clinical strains. However, in the current study, the 
level of vancomycin resistance was not low and the 
presence of van genes other than vanA was not 
excluded.  
Randomly amplified polymorphic DNA was previously 
used for typing MRSA (Tambic et al., 1997). The present 
study provided a molecular typing by RAPD for the 
reported VRSA strains using four different pairs of 





this method, and at the genetic distance value of 15, the 
resultant dendrogram divides the isolates into four 
groups. With the exception of isolate 1, all the ten 
vancomycin resistant S. aureus strains were found at the 
first group. Additionally, all VRSA isolates had the same 
vancomycin MIC and antibiotic sensitivity pattern. Four 
out of five VRSA isolates that had vanA gene (the same 
vancomycin MIC and antibiotic sensitivity pattern) were 
also isolated from ICU (isolates 6, 7, 8, 9). They have 
similarity index according to RAPD of 0.5, 0.6, 0.6, 0.8, 
0.5, 0.7 for isolates 6, 7 and 6, 8 and 6, 9 and 7, 8 and 7, 
9 and 8, 9, respectively. This means that some of them 
may be related strains transmitted from one patient to 
another or derived from a common origin strain 
(especially the very close strains 7, 8). Additionally, 
isolate 5 (from ICU, same vancomycin MIC and antibiotic 
sensitivity pattern) showed the same RAPD pattern of 
isolate 8 (similarity index1.0), which may mean that they 
are the same strain except that isolate 5 lack vanA gene 
as tested by multiplex PCR. This may be explained if 
isolate 5 lost the gene carrying plasmid or enough 
number of the gene copies that it become undetectable 
by PCR, but still vancomycin resistant as it may be 
multifactorial process (Wong et al., 1999).  
Meanwhile, it is not clear if vanA gene presence, its 
copy number or expression is related also to the reported 
reversible mechanism of vancomycin resistance (Cui et 
al., 2003). Isolates 2, 3 were also very close (RAPD 
similarity index 0.8, no vanA gene, same vancomycin 
MIC and antibiotic sensitivity, from orthopedic ward). The 
general observation is that the clonal diversity among 
VRSA isolates in the current study was small (RAPD, 
MIC, antibiotic sensitivity). This may indicate that most of 
them were derived from common origin strains. 
Therefore, more studies are still needed to explore the 
definite mechanisms by which these strains acquire 
resistance to vancomycin which may open the door to 
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